Mexicor - instructions for use, reviews, analogs and forms of release (capsules or tablets 100 mg, injections in injections) of a drug for the treatment of IHD, stroke and encephalopathy in adults, children and pregnancy. Composition

In this article, you can read the instructions for using the drug Mexicore. Presented are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors of specialists on the use of Mexicor in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Mexico in the presence of existing structural analogues.Use for the treatment of coronary heart disease (CHD), stroke and encephalopathy in adults, children, as well as during pregnancy and lactation. Composition of the preparation.

Mexicore antioxidant drug.

Mexicor reduces manifestations of oxidative stress, inhibiting free radical peroxide oxidation of lipids and increasing the activity of the antioxidant system of enzymes. Mexicor improves cellular energy metabolism by activating the energy-synthesizing functions of mitochondria, enhancing compensatory activation of aerobic glycolysis and reducing the degree of inhibition of oxidative processes in the Krebs cycle.

The energosynthesizing effect of the drug is associated with an increase in the delivery and consumption of succinate cells, the realization of the phenomenon of rapid oxidation of succinic acid with succinate dehydrogenase, and with the activation of the mitochondrial respiratory chain. When dissociation of Mexocorp in the cell to succinate and the 3-hydroxypyridine derivative (base), the base exhibits a powerful antioxidant effect, stabilizing the cell membranes and restoring the functional activity of the cells.Reduces the viscosity of the cell membrane, increases its fluidity and modulates membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), ion channels and receptor complexes, which contributes to the preservation of the structural and functional integrity of biomembranes, improves neurotransmitter transport and synaptic transmission.

The drug improves cerebral metabolism and blood supply to the brain, improves microcirculation and rheological properties of blood, reduces platelet aggregation.

It improves the functional state of the ischemic myocardium, the contractile function of the heart, and also reduces the manifestations of systolic and diastolic dysfunction of the left ventricle. In conditions of coronary insufficiency increases the collateral blood supply of the ischemic myocardium and activates the energosynthesizing processes in the ischemic zone, which contributes to the preservation of the integrity of cardiomyocytes and the maintenance of their functional activity. Effectively restores myocardial contractility with reversible cardiac dysfunction, which represents a significant reserve for increasing the contractility of the heart in patients with IHD,complicated by heart failure.

In patients with stable angina, stress increases tolerance to physical activity and antianginal activity of nitrates, improves the rheological properties of blood. Adding Mexicor to standard CHD therapy improves the clinical state of patients, increasing tolerance to physical activity and improving the quality of life.

Mexicor stabilizes the membrane structures of the vascular wall, inhibits platelet aggregation, normalizes microcirculation disorders in the early stages of atherogenesis, has lipid-lowering effect, reduces the content of total cholesterol and LDL.

Mexicor has a neuroprotective effect on the functional activity and metabolism of the ischemic brain, improves the stability of blood circulation in the brain under hypoperfusion conditions, prevents the reduction of brain blood flow in the reperfusion period after ischemia. The drug contributes to adaptation to the damaging effect of ischemia, inhibiting the depletion of carbohydrate reserves, blocking the postischemic decline in the utilization of glucose and oxygen by the brain and preventing the progressive accumulation of lactate.At the same time, the indices of autoregulatory reactions of cerebral vessels improve.

Mexicor possesses nootropic properties, it prevents and reduces the learning and memory process disruptions that occur in acute and chronic vascular diseases of the brain, with mild and moderate cognitive impairments of various genesis, has an antioxidant effect, increases concentration and performance.

The inclusion of Mexicor in the complex therapy of patients with acute impairment of cerebral circulation reduces the severity of clinical manifestations of stroke and improves the course of the rehabilitation period.

Mexicor has a selective, not accompanied by sedation and muscle relaxation, anxiolytic action, eliminates anxiety, fear, tension, anxiety, increases adaptation and emotional status.

Composition

Ethyl methylhydroxypyridine succinate + auxiliary substances.

Pharmacokinetics

After ingestion, the active substance of the Mexicor preparation is quickly and completely absorbed from the digestive tract. Quickly distributed in organs and tissues. The average time of distribution of the drug in the body is 4.9-5.2 hours.

Metabolized in the liver by glucuronation.Five metabolites were identified: 3-hydroxypyridine phosphate - is formed in the liver and, with the participation of alkaline phosphatase, decomposes into phosphoric acid and 3-hydroxypyridine; 2-nd metabolite - pharmacologically active, is formed in large quantities and is found in the urine for 1-2 days after taking the drug; 3rd - is excreted in large quantities by the kidneys; 4-th and 5-th - glucuronconjugates. The most active substance and its glucuronoconjugates are excreted in the first 4 hours after taking the drug. The indicators of excretion of the unchanged drug and metabolites by the kidneys have a significant individual variability.

Indications

• IHD (as part of complex therapy);
• in the complex therapy of acute myocardial infarction (from the first day);
• ischemic stroke (as part of complex therapy);
• encephalopathy;
• mild to moderate cognitive impairment.

Forms of release

Capsules 100 mg (sometimes mistakenly called pills).

Solution for intravenous and intramuscular injection (injections in ampoules for injection).

Instructions for use and dosing regimen

Capsules

Mexicore is prescribed inside. The initial dose is 100 mg (1 capsule) 3 times a day.Next, you should gradually increase the dose depending on the clinical course of the disease and the tolerability of the therapy. The maximum daily dose should not exceed 800 mg, single dose - 200 mg. The daily dose of the drug is preferably divided into several doses during the day. The course of treatment with Mexico is completed gradually, reducing the daily dose of the drug by 100 mg.

The duration of the course of therapy by Mexico when applying it in the complex therapy of IHD and circulatory disorders of the brain should be at least 1.5-2 months. Repeated courses (on the recommendation of a doctor), preferably in the spring-autumn periods.

With complex therapy of dyscirculatory encephalopathy, mild and moderate cognitive disorders, Mexicor is prescribed without restriction of the course of treatment for duration, in a dose of 100 mg 3-4 times a day.

Ampoules

In the treatment of acute myocardial infarction, Mexicor is administered intravenously or intramuscularly for 14 days against a background of traditional therapy, including nitrates, beta-blockers, ACE inhibitors, thrombolytics, anticoagulants and antiplatelet agents, as well as symptomatic drugs according to indications.

In the first 5 days to achieve maximum effect, the drug should be administered iv, in the next 9 days - the drug can be injected / m.

In / in the introduction of the drug is carried out by dropwise infusion, slowly (to avoid side effects), in physiological saline or 5% solution of Dextrose (glucose) in a volume of 100-150 ml for 30-90 minutes. If necessary, a slow jet injection of a preparation lasting not less than 5 minutes is possible.

Parenteral administration of the drug (iv or IM) is carried out 3 times a day, every 8 hours. The daily therapeutic dose is 6-9 mg / kg of body weight, a single dose of 2-3 mg / kg of body weight. The maximum daily dose should not exceed 800 mg, single dose - 250 mg.

In acute disorders of cerebral circulation (ischemic stroke), Mexicor is used as a part of complex therapy in the first 2-4 days IV drip in 200-300 mg 2-3 times a day, then in / m at 100 mg 3 times a day. The duration of treatment is 10-14 days. In the future, the drug is administered orally in the form of capsules of 100 mg twice a day for 14 days and 100 mg 3 times daily for the next 7 days. The frequency and duration of repeated courses of therapy is determined by the physician.

In dyscirculatory encephalopathy in the phase of decompensation, Mexicor should be used iv / drip or drip in a dose of 100 mg 2-3 times per day for 14 days. Then the drug is given in / m at 100 mg per day for the next 2 weeks. In the future, the drug is prescribed in the form of capsules of 100 mg 2-4 times a day, the frequency and duration of therapy is determined by the doctor.

For the course of prophylaxis of discirculatory encephalopathy, Mexicor is given intravenously in a dose of 100 mg twice a day for 10-14 days.

For the treatment of mild and moderate cognitive disorders, Mexicor is given a / m dose of 100-300 mg per day for 14 days. If necessary, in the future, the drug is used in capsular form for 100 mg 2-4 times a day (on the recommendation of a doctor) without limiting the course of treatment for duration.

Side effect

• dryness and metallic taste in the mouth;
• sore throat;
• feeling of discomfort in the chest and lack of air;
• sensation of "spilling" heat throughout the body;
• dyspepsia;
• nausea;
• diarrhea;
• flatulence;
• allergic reactions;
• sleep disturbances (drowsiness or falling asleep).

Contraindications

• impaired liver function;
• impaired renal function;
• children and adolescents under 18 years of age (efficacy and safety not established);
• pregnancy;
• lactation (breastfeeding);
• hypersensitivity to the components of the drug.

Application in pregnancy and lactation

Contraindicated use of the drug during pregnancy and lactation.

Use in children

Contraindicated in children and adolescents under the age of 18 years. The effectiveness and safety of appointing Mexico to children and adolescents under the age of 18 years are not established.

special instructions

In acute myocardial infarction, acute (ischemic stroke) and chronic (dyscirculatory encephalopathy) disorders of cerebral circulation after the completion of parenteral administration of the drug, it is recommended to continue the use of the drug Mexocor in the dosage form of the capsule (100 mg 3 times per day) in order to maintain the therapeutic effect. The duration of therapy is determined by the doctor.

Impact on the ability to drive vehicles and manage mechanisms

During the period of drug treatment, care should be taken when driving vehicles and engaging in other potentially hazardous activities,requiring increased concentration of attention and speed of psychomotor reactions.

Drug Interactions

Mexicor enhances the action of anticonvulsants (carbamazepine), antiparkinsonics (levodopa) and benzodiazepine anxiolytics.

Mexicor reduces the toxic effects of ethanol (alcohol).

Mexicor potentiates the effect of nitrates.

Analogues of Mexicor drug

Structural analogs for the active substance:

• 2-ethyl-6-methyl-3-hydroxypyridine succinate;
• 3-hydroxy-6-methyl-2-ethylpyridine succinate;
• Medomexi;
• Mexidant;
• Mexidol;
• Mexipridol;
• Mexiprim;
• Mexicin;
• Metostabil;
• Neurox;
• Cerekard;
• Ethyl methylhydroxypyridine succinate.

Similar medicines:

Other medicines: